Phraxis Inc

Phraxis is a medical device company specializing in innovative endovascular solutions for hemodialysis access. The company's flagship product, EndoForce™ Connector, is an FDA-approved device designed to create arteriovenous grafts (AVG) for hemodialysis patients using a minimally invasive, endovascular approach. EndoForce™ eliminates the need for surgical dissection required in traditional sutured anastomosis techniques and enables precise, coaxial vessel-to-graft alignment through standard transcatheter methods. The device features a patented design incorporating a flexible nitinol segment for versatile implantation angles and a rigid segment with nitinol barbs for secure attachment. In pivotal clinical trials, EndoForce™ demonstrated a 92% cumulative patency rate, exceeding the 80% rate associated with conventional suture anastomosis, thereby extending graft longevity and reducing complications. The company was founded by Dr. Alex Yevzlin, an interventional nephrologist whose clinical expertise in dialysis access informed the product's development. Phraxis targets nephrology and vascular surgery markets, addressing critical clinical challenges in hemodialysis access creation with a precision-engineered, reproducible endovascular solution.